Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...
BioXcel Therapeutics Announces Reverse Stock Split
Following the reverse stock split, the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "BTAI" with the new CUSIP number, 09075P204. The reverse stock split ...
DelveInsight Business Research, LLP: Global Biologics Drug Substance Manufacturing Market to Exhibit Growth at a CAGR of ~11% by 2032 | DelveInsight
The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...